必须声明标量变量 "@Script_ID"。 喹硫平治疗精神障碍研究进展-《赣南医学院学报》

[1]蒲强红,吕秋菊,王俊.喹硫平治疗精神障碍研究进展[J].赣南医学院学报,2015,(01):156-159.
 Pu Qiang-hong Lv Qiu-ju Wang Jun.Quetiapine for the treatment of psychiatric disorders: anxiety spectrum disorders, behavioral and psychological symptoms of dementia, insomnia, alcoholism[J].,2015,(01):156-159.
点击复制

喹硫平治疗精神障碍研究进展()
分享到:

《赣南医学院学报》[ISSN:1001-5779/CN:36-1154/R]

卷:
期数:
2015年01期
页码:
156-159
栏目:
出版日期:
2015-02-28

文章信息/Info

Title:
Quetiapine for the treatment of psychiatric disorders: anxiety spectrum disorders, behavioral and psychological symptoms of dementia, insomnia, alcoholism
作者:
蒲强红1吕秋菊2王俊3
1.乐山职业技术学院;2.乐山市人民医院;3.乐山市精神病医院,四川乐山614000
Author(s):
Pu Qiang-hong1 Lv Qiu-ju2 Wang Jun3
1: Leshan vocational & technical college, 2:The people’s hospital of Leshan,3. Leshan psychiatric hospital, Leshan city, Sichuan province 614000
关键词:
喹硫平焦虑谱系障碍痴呆的精神行为症状失眠症酒精依赖症
Keywords:
quetiapine anxiety spectrum disorders behavioral and psychological symptoms of dementia insomnia alcoholism
文献标志码:
A
摘要:
非典型抗精神病药喹硫平临床应用广泛,已批准用于治疗精神分裂症、心境障碍(急性躁狂发作、双相障碍、重度抑郁等)。临床试验发现喹硫平可治疗焦虑谱系障碍、痴呆的精神行为症状、失眠症、酒精依赖症等精神障碍。故本文主要综述喹硫平治疗焦虑谱系障碍、痴呆的精神行为症状、失眠症、酒精依赖症等精神障碍的随机对照试验结果,以期为精神科医生用药提供参考依据。更多还原
Abstract:
Atypical antipsychotic drug quetiapine was approved for the treatment of schizophrenia, acute mania, acute bipolar disorder and major depression. Some clinical trials provided evidences for the efficacy of quetiapine in the anxiety spectrum disorders, behavioral and psychological symptoms of dementia, insomnia, alcoholism. This paper reviewed mainly the results of quetiapine in the treatment for anxiety spectrum disorders, behavioral and psychological symptoms of dementia, insomnia, alcoholism in random control trials.

参考文献/References:

[1]Bandelow B.,Chouinard G.,Bobes J.,et al.Extendedrelease quetiapine fumarate (quetiapine XR):a oncedaily monotherapy effective in generalized anxiety disorder.Data from a randomized,doubleblind,placeboand activecontrolled study[J].The International Journal of Neuropsychopharmacology,2010,13(3):305-320.
[2]Khan A.,Joyce M.,Atkinson S.,et al.A randomized, doubleblind study of oncedaily extended release quetiapine fumarate (quetiapine XR) monotherapy in patients with generalized anxiety disorder[J].J Clin Psychopharmacol,2011,31(4):418-28.
[3]Merideth C.,Cutler A. J.,She F.,et al.Efficacy and tolerability of extended release quetiapine fumarate monotherapy in the acute treatment of generalized anxiety disorder: a randomized,placebo controlled and activecontrolled study[J].Int Clin Psychopharmacol,2012, 27(1):40-54.
[4]Simon N. M.,Connor K. M.,LeBeau R. T.,et al.Quetiapine augmentation of paroxetine CR for the treatment of refractory generalized anxiety disorder:preliminary findings[J].Psychopharmacology (Berl),2008,197(4):675-681.
[5]Katzman M.,Vermani M.,Jacobs L.,et al.Quetiapine as an adjunctive pharmacotherapy for the treatment of nonremitting generalized anxiety disorder:a flexibledose,openlabel pilot trial[J].Journal of anxiety disorders,2008,22(8):1480-1486.
[6]Denys D.,de Geus F.,van Megen H. J.,et al.A double-blind, randomized,placebocontrolled trial of quetiapine addition in patients with obsessivecompulsive disorder refractory to serotonin reuptake inhibitors[J].Journal of clinical psychiatry,2004,65(8):1040-1048.
[7]Carey P. D., Vythilingum B., Seedat S., et al. Quetiapine augmentation of SRIs in treatment refractory obsessive-compulsive disorder: a double-blind, randomised, placebo-controlled study[ISRCTN83050762][J].BMC psychiatry,2005, 5(1):5.
[8]Fineberg N. A., Sivakumaran T., Roberts A., et al. Adding quetiapine to SRI in treatment-resistant obsessive-compulsive disorder: a randomized controlled treatment study[J].Int Clin Psychopharmacol,2005, 20(4):223-226.
[9]Kordon A.,Wahl K.,Koch N.,et al.Quetiapine Addition to Serotonin Reuptake Inhibitors in Patients With Severe Obsessive-Compulsive Disorder: A Double-Blind, Randomized, Placebo-Controlled Study[J].J Clin Psychopharmacol,2008, 28(5):550-554.
[10]de Geus F., Denys D. and Westenberg H. G. Effects of quetiapine on cognitive functioning in obsessive-compulsive disorder[J].Int Clin Psychopharmacol,2007, 22(2):77-84.
[11]Matsunaga H., Nagata T., Hayashida K., et al. A long-term trial of the effectiveness and safety of atypical antipsychotic agents in augmenting SSRI-refractory obsessive-compulsive disorder[J].The Journal of clinical psychiatry,2009, 70(6):863-868.
[12]Bloch M., Landeros-Weisenberger A., Kelmendi B., et al. A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder[J]. Molecular psychiatry,2006, 11(7):622-632.
[13]Vulink N. C., Denys D., Fluitman S. B., et al. Quetiapine augments the effect of citalopram in non-refractory obsessive-compulsive disorder: a randomized, double-blind, placebo-controlled study of 76 patients[J].Journal of clinical psychiatry,2009, 70(7):1001-1008.
[14]Vaishnavi S., Alamy S., Zhang W., et al. Quetiapine as monotherapy for social anxiety disorder: a placebo-controlled study[J].Progress in Neuro-Psychopharmacology and Biological Psychiatry,2007, 31(7):1464-1469.
[15]Donahue C. B., Kushner M. G., Thuras P. D., et al. Effect of quetiapine vs. placebo on response to two virtual public speaking exposures in individuals with social phobia[J].Journal of anxiety disorders,2009, 23(3):362-368.
[16]Kozaric-Kovacic D. and Pivac N. Quetiapine treatment in an open trial in combat-related post-traumatic stress disorder with psychotic features[J].The International Journal of Neuropsychopharmacology,2007, 10(2):253-261.
[17]Byers M. G., Allison K. M., Wendel C. S., et al. Prazosin versus quetiapine for nighttime posttraumatic stress disorder symptoms in veterans: an assessment of long-term comparative effectiveness and safety[J].J Clin Psychopharmacol,2010, 30(3):225-9.
[18]Hamner M. B.,Deitsch S. E.,Brodrick P. S.,et al.Quetiapine treatment in patients with posttraumatic stress disorder: an open trial of adjunctive therapy[J].J Clin Psychopharmacol,2003, 23(1):15-20.
[19]Ahearn E. P.,Mussey M.,Johnson C.,et al.Quetiapine as an adjunctive treatment for post-traumatic stress disorder: an 8-week open-label study[J].Int Clin Psychopharmacol,2006, 21(1):29-33.
[20]Ballard C.,Margallo-Lana M., Juszczak E., et al. Quetiapine and rivastigmine and cognitive decline in Alzheimer's disease: randomised double blind placebo controlled trial[J].Bmj,2005, 330(7496):874.
[21]Paleacu D., Barak Y., Mirecky I., et al. Quetiapine treatment for behavioural and psychological symptoms of dementia in Alzheimer's disease patients: a 6-week, double-blind, placebo-controlled study[J]. Int J Geriatr Psychiatry,2008, 23(4):393-400.
[22]Tariot P. N., Schneider L., Katz I. R., et al. Quetiapine treatment of psychosis associated with dementia: a double-blind, randomized, placebo-controlled clinical trial[J]. Am J Geriatr Psychiatry,2006, 14(9):767-76.
[23]Schneider L. S., Tariot P. N., Dagerman K. S., et al. Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease[J]. N Engl J Med,2006, 355(15):1525-38.
[24]Zhong K. X., Tariot P. N., Mintzer J., et al. Quetiapine to treat agitation in dementia: a randomized, double-blind, placebo-controlled study[J].Curr Alzheimer Res,2007, 4(1):81-93.
[25]Sultzer D. L., Davis S. M., Tariot P. N., et al. Clinical symptom responses to atypical antipsychotic medications in Alzheimer's disease: phase 1 outcomes from the CATIE-AD effectiveness trial[J].Am J Psychiatry,2008, 165(7):844-54.
[26]Cheung G. and Stapelberg J. Quetiapine for the treatment of behavioural and psychological symptoms of dementia (BPSD): a meta-analysis of randomised placebo-controlled trials[J].NZ Med J,2011, 124(1336):39-50.
[27]Garakani A., Martinez J. M., Marcus S., et al. A randomized, double-blind, and placebo-controlled trial of quetiapine augmentation of fluoxetine in major depressive disorder[J].Int Clin Psychopharmacol,2008, 23(5):269-75.
[28]唐开旺, 邝云航, 张瑜良, 等. 小剂量喹硫平对失眠症患者睡眠质量及心理健康状况的影响[J]. 临床心身疾病杂志,2012, 18(002):156-159.
[29]胡芳珍, 陈华强, 陈军良, 等. 小剂量喹硫平治疗顽固性失眠的疗效观察[J]. 中国药物滥用防治杂志,2011, 17(5):263-265.
[30]Kampman K. M., Pettinati H. M., Lynch K. G., et al. A double-blind, placebo-controlled pilot trial of quetiapine for the treatment of Type A and Type B alcoholism[J].J Clin Psychopharmacol,2007, 27(4):344-51.
[31]Litten R. Z., Fertig J. B., Falk D. E., et al. A double-blind, placebo-controlled trial to assess the efficacy of quetiapine fumarate XR in very heavy-drinking alcohol-dependent patients[J]. Alcohol Clin Exp Res,2012, 36(3):406-16.

更新日期/Last Update: 1900-01-01